In my last article , I stated that the fear surrounding Novo Nordisk A/S ( NVO ); ( OTCPK:NONOF ) was overblown. At that time, concerns about competition and the sustainability of NVO's growth in their weight loss segment dimmed investors' confidence. The stock hasn'tGerman Buy-Hold-Check investor. With a master's degree in engineering and management, I am able to understand, quantify, and interpret both the economics and (to some point) the technology of companies.Analyst’s Disclosure:I/we have a beneficia ...